GeNeuro S.A.
PAR: GNRO.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jesus Martin-Garcia
- Employees
- 17
- Headquarters
- Plan-les-Ouates, Switzerland
- IPO year
- 2016
- Market cap
- €908.2K
- Website
- https://www.geneuro.com
Loading GNRO…
Loading profile data…Frequently asked questions about GNRO
What does GeNeuro S.A. (GNRO.PA) do?
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Ph...
Where does GNRO.PA trade?
GeNeuro S.A. (GNRO.PA) trades on the Euronext Paris.
What sector is GNRO.PA in?
GeNeuro S.A. (GNRO.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GeNeuro S.A.?
Jesus Martin-Garcia is the chief executive officer of GeNeuro S.A. (GNRO.PA).
Where is GeNeuro S.A. headquartered?
GeNeuro S.A. is headquartered in Switzerland.
Does GNRO.PA pay a dividend?
GeNeuro S.A. (GNRO.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GNRO.PA go public?
GeNeuro S.A. (GNRO.PA) completed its initial public offering in 2016.